木樨草素等抗心肌缺血/再灌注损伤及抑制脂代谢和细胞凋亡作用研究
Effects of Luteolin and Its Analogues Against Myocardial Ischemia/Reperfusion Injury, Lipid Metabolism and Apoptosis
-
摘要: 目的 探讨香青兰中木樨草素、山奈酚和木樨草苷对大鼠离体心肌缺血/再灌注损伤(MIRI)模型的保护作用及其抑制脂代谢相关酶11β-羟基类固醇脱氢酶1型(11β-HSD1)、溶血磷脂酸酰基转移酶(LPAATs)和细胞凋亡相关蛋白磷酸酯酶和张力蛋白同系物(PTEN)、蛋白酪氨酸磷酸酶2(SHIP-2)的作用,探讨中药多成分、多靶点抗MIRI的机制。方法 采用Langendorff装置,以洛-林二氏溶液为灌流液,通过停灌和复灌心脏建立MIRI模型,检测心率(HR)、左室舒张末压(LVEDP)、左室发展压(LVDP)、(-dp/dt)/(+dp/dt)、冠脉流量(CF)、乳酸脱氢酶(LDH)、心肌梗死面积。ELISA法测定LPAATβ和11β-HSD1活性。分光光度法测定PTEN和SHIP-2活性。结果 木樨草素、山奈酚和木樨草苷保护HR,降低LDH过量释放,升高LVEDP、LVDP和(-dp/dt)/(+dp/dt),恢复CF,降低心肌梗死面积。LPAATβ、11β-HSD1、PTEN、SHP-2等蛋白活性受木樨草素等的抑制。结论 木樨草素、山奈酚和木樨草苷具有通过抗脂代谢紊乱和抗细胞凋亡分子机制保护大鼠离体心脏MIRI的作用。Abstract: OBJECTIVE To explore the multi-component and on MIRI model rat multi-target mechanism of Chinese medicine against MIRI, the protective effects of luteolin, kaempferol and luteoloside on rat MIRI, and the inhibition on lipid-metabolization-related enzymes 11β-HSD1, LPAATβ, and apoptosis-related enzymes PTEN, and SHP-2. METHEODS Using a Langendorff apparatus, the MIRI model was established by stopping perfusion and reperfusion with oxygenated Locke-Ringer's solution. The HR, LVEDP, LVDP, (-dp/dt)/(+dp/dt), CF, LDH and myocardial infarct size were assayed. LPAATβ and 11β-HSD1 were assayed by spectrophotometry. The inhibition of PTEN and SHP-2 activity was measured by spectrophotometry. RESULTS Luteolin, kaempferol and luteoloside could protect HR, reduce LDH release, raise LVDP, LVEDP and (-dp/dt)/ (+dp/dt), recover CF, and reduce myocardial infarct size, respectively. Moreover, the activities of LPAATβ, 11β-HSD1, PTEN and SHP-2 were repressed by pretreatment with luteolin, kaempferol and luteoloside. CONCLUSION Luteolin, kaempferol and luteoloside show the cardioprotective effects on MIRI of isolated rat heart by against lipid metabolism disorders and apoptosis.
-
Key words:
- luteolin /
- kaempferol /
- luteoloside /
- myocardial ischemia/reperfusion injury /
- 11β-HSD1 /
- LPAATβ /
- PTEN /
- SHP-2
-
[1] HEUSCH G.Critical issues for the translation of cardioprotection[J].Circ Res,2017,120(9):1477-1486. [2] HEUSCH G.Cardioprotection research must leave its comfort zone[J].Eur Heart J,2018,39(36):3393-3395. [3] 吴楠,张晓雯.高脂血症对心肌缺血再灌注损伤的影响[J].解剖科学进展,2019,25(6):724-726,730. [4] FERDINANDY P,HAUSENLOY DJ,HEUSCH G,et al.Interaction of risk factors,comorbidities,and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning,postconditioning,and remote conditioning[J].Pharmacol Rev,2014,66(4):1142-1174. [5] PEREIRA CD,AZEVEDO I,MONTEIRO R,et al.11β-Hydroxysteroid dehydrogenase type 1:Relevance of its modulation in the pathophysiology of obesity,the metabolic syndrome and type 2 diabetes mellitus[J].Diabetes Obes Metab,2012,14(10):869-881. [6] ZHUKOVSKY MA,FILOGRANA A,LUINI A,et al.The structure and function of acylglycerophosphate acyltransferase 4/ lysophosphatidic acid acyltransferase delta (AGPAT4/LPAATδ)[J].Front Cell Dev Biol,2019,7:147. [7] TANG WW,YUAN J,CHEN XY,et al.Identification of a novel human lysophosphatidic acid acyltransferase,LPAAT-theta,which activates mTOR pathway[J].J Biochem Mol Biol,2006,39(5):626-635. [8] SAULNIER-BLACHE JS,GIRARD A,SIMON MF,et al.A simple and highly sensitive radioenzymatic assay for lysophosphatidic acid quantification[J].J Lipid Res,2000,41(12):1947-1951. [9] HIDESHIMA T,CHAUHAN D,HAYASHI T,et al.Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors,a novel class of agents,in multiple myeloma[J].Cancer Res,2003,63(23):8428-8436. [10] WU DN,PEI DS,WANG Q,et al.Down-regulation of PTEN by sodium orthovanadate inhibits ASK1 activation via PI3-K/Akt during cerebral ischemia in rat Hippocampus[J].Neurosci Lett,2006,404(1/2):98-102. [11] MOCANU MM,YELLON DM.PTEN,the Achilles' heel of myocardial ischaemia/reperfusion injury?[J].Br J Pharmacol,2007,150(7):833-838. [12] KEYES KT,XU J,LONG B,et al.Pharmacological inhibition of PTEN limits myocardial infarct size and improves left ventricular function postinfarction[J].Am J Physiol Heart Circ Physiol,2010,298(4):H1198-H1208. [13] CHAN RJ,FENG GS.PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase[J].Blood,2007,109(3):862-867. [14] LEE SW,WON JY,LEE HY,et al.Angiopoietin-1 protects heart against ischemia/reperfusion injury through VE-cadherin dephosphorylation and myocardiac integrin-β1/ERK/caspase-9 phosphorylation cascade[J].Mol Med,2011,17(9/10):1095-1106. [15] 阿布卡德,田友清,尚靖.香青兰研究进展[J].北方药学,2011,8(2):55-57. [16] 阿布力米提,艾来提,穆赫塔尔,等.香青兰中黄酮类化合物的研究[J].食品科学,2007,28(8):384-386. [17] 谭梦晖,于波,谷颖敏,等.香青兰不同部位提取物对大鼠实验性高脂血症的影响[J].中国实验方剂学杂志,2011,17(21):209-213. [18] 田友清,尚靖,何婷,等.基于中药血清化学及血清药理学方法探讨香青兰保护心肌细胞缺氧/复氧损伤物质基础[J].中国中药杂志,2012,37(5):620-624. [19] 田友清,尚靖,阿布卡德.香青兰及其含药血清对H9c2心肌细胞三种缺氧/复氧损伤模型的影响[J].中国新药杂志,2012,21(15):1736-1739,1748. [20] 李梦雯,于东升,田友清,等.木犀草素对心肌细胞物理性及化学性缺氧/复氧损伤的作用[J].中国药学杂志,2013,48(17):1257-1261. [21] YU DS,LI MW,TIAN YQ,et al.Luteolin inhibits ROS-activated MAPK pathway in myocardial ischemia/reperfusion injury[J].Life Sci,2015,122:15-25. [22] ZHOU MJ,REN HH,HAN JC,et al.Protective effects of kaempferol against myocardial ischemia/reperfusion injury in isolated rat heart via antioxidant activity and inhibition of glycogen synthase kinase-3β[J].Oxid Med Cell Longev,2015,2015:481405. [23] STILES B,GROSZER M,WANG SY,et al.PTENless means more[J].Dev Biol,2004,273(2):175-184. [24] 黄定德,陈杞,韩玲,等.γ线诱发的白血病小鼠胸腺细胞中SHP-2表达及功能的研究[J].第三军医大学学报,2004,26(14):1258-1260.
点击查看大图
计量
- 文章访问数: 522
- HTML全文浏览量: 6
- PDF下载量: 392
- 被引次数: 0